{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:24:39Z","timestamp":1757780679954,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PRIN 2012"},{"name":"ESCMID Study Group Research Grant"},{"name":"Swiss National Science Foundation Grants","award":["189136"],"award-info":[{"award-number":["189136"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Meningococcal meningitis (MM) is a life-threatening disease associated with approximately 10% case fatality rates and neurological sequelae in 10\u201320% of the cases. Recently, we have shown that the matrix metalloproteinase (MMP) inhibitor BB-94 reduced brain injury in a mouse model of MM. The present study aimed to assess whether doxycycline (DOX), a tetracycline that showed a neuroprotective effect as adjuvant therapy in experimental pneumococcal meningitis (PM), would also exert a beneficial effect when given as adjunctive therapy to ceftriaxone (CRO) in experimental MM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>BALB\/c mice were infected by the intracisternal route with a group C<jats:italic>Neisseria meningitidis<\/jats:italic>strain. Eighteen h post infection (hpi), animals were randomised for treatment with CRO [100\u2009mg\/kg\u2009subcutaneously (s.c.)], CRO plus DOX (30\u2009mg\/kg\u2009s.c.) or saline (control\u00a0s.c.). Antibiotic treatment was repeated 24 and 40 hpi. Mouse survival and clinical signs, bacterial counts in cerebella, brain damage, MMP-9 and cyto\/chemokine levels were assessed 48 hpi.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Analysis of bacterial load in cerebella indicated that CRO and CRO\u2009+\u2009DOX were equally effective at controlling meningococcal replication. No differences in survival were observed between mice treated with CRO (94.4%) or CRO\u2009+\u2009DOX (95.5%), (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Treatment with CRO\u2009+\u2009DOX significantly diminished both the number of cerebral hemorrhages (<jats:italic>p<\/jats:italic>\u2009=\u20090.029) and the amount of MMP-9 in the brain (<jats:italic>p<\/jats:italic>\u2009=\u20090.046) compared to untreated controls, but not to CRO-treated animals (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Levels of inflammatory markers in the brain of mice that received CRO or CRO\u2009+\u2009DOX were not significantly different (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Overall, there were no significant differences in the parameters assessed between the groups treated with CRO alone or CRO\u2009+\u2009DOX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Treatment with CRO\u2009+\u2009DOX showed similar bactericidal activity to CRO in vivo, suggesting no antagonist effect of DOX on CRO. Combined therapy significantly improved mouse survival and disease severity compared to untreated animals, but addition of DOX to CRO did not offer significant benefits over CRO monotherapy. In contrast to experimental PM, DOX has no adjunctive activity in experimental MM.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12879-020-05226-w","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T12:06:02Z","timestamp":1594641962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combined therapy with ceftriaxone and doxycycline does not improve the outcome of meningococcal meningitis in mice compared to ceftriaxone monotherapy"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6391","authenticated-orcid":false,"given":"Susanna","family":"Ricci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Grandgirard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilias","family":"Masouris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Braccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco R.","family":"Oggioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Koedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen L.","family":"Leib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"5226_CR1","doi-asserted-by":"crossref","first-page":"16074","DOI":"10.1038\/nrdp.2016.74","volume":"2","author":"D van de Beek","year":"2016","unstructured":"van de Beek D, Brouwer M, Hasbun R, Koedel U, Whitney CG, Wijdicks E. Community-acquired bacterial meningitis. Nature Rev Dis Primers. 2016;2:16074.","journal-title":"Nature Rev Dis Primers"},{"key":"5226_CR2","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","volume":"30S","author":"D Pace","year":"2012","unstructured":"Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30S:B3\u20139.","journal-title":"Vaccine"},{"key":"5226_CR3","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report. In: Emerging Infections Program Network, Neisseria meningitidis. 2018. http:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/mening18.pdf."},{"key":"5226_CR4","volume-title":"ECDC. Annual epidemiological report for 2017","author":"European Centre for Disease Prevention and Control","year":"2019","unstructured":"European Centre for Disease Prevention and Control. Invasive meningococcal disease. In: ECDC. Annual epidemiological report for 2017. Stockolm: ECDC; 2019."},{"key":"5226_CR5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","volume":"7","author":"KJ Olbrich","year":"2018","unstructured":"Olbrich KJ, Muller D, Schumacher S, Beck E. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7:421\u201338.","journal-title":"Infect Dis Ther"},{"key":"5226_CR6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1473-3099(10)70048-7","volume":"10","author":"K Edmond","year":"2010","unstructured":"Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:317\u201328.","journal-title":"Lancet Infect Dis"},{"key":"5226_CR7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/QCO.0b013e328337f49e","volume":"23","author":"U Koedel","year":"2010","unstructured":"Koedel U, Klein M, Pfister H-W. New understandings on the pathophysiology of bacterial meningitis. Curr Opin Infect Dis. 2010;23:217\u201323.","journal-title":"Curr Opin Infect Dis"},{"key":"5226_CR8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/WCO.0b013e32833950dd","volume":"23","author":"J Gerber","year":"2010","unstructured":"Gerber J, Nau R. Mechanisms of injury in bacterial meningitis. Curr Opin Neurol. 2010;23:312\u20138.","journal-title":"Curr Opin Neurol"},{"key":"5226_CR9","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2217\/fmb.15.43","volume":"10","author":"FD Liechti","year":"2015","unstructured":"Liechti FD, Grandgirard D, Leib SL. Bacterial meningitis: insights into pathogenesis and evaluation of new treatment options: a perspective from experimental studies. Future Microbiol. 2015;10:1195\u2013213.","journal-title":"Future Microbiol"},{"key":"5226_CR10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nri1418","volume":"4","author":"WC Parks","year":"2004","unstructured":"Parks WC, Wilson CL, Lopez-Boado Y. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol. 2004;4:617\u201329.","journal-title":"Nat Rev Immunol"},{"key":"5226_CR11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0165-0173(01)00101-1","volume":"36","author":"D Leppert","year":"2001","unstructured":"Leppert D, Lindberg RLP, Kappos L, Leib SL. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitidis. Brain Res Rev. 2001;36:249\u201357.","journal-title":"Brain Res Rev"},{"key":"5226_CR12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/B978-0-444-63486-3.00014-1","volume":"214","author":"K Baranger","year":"2014","unstructured":"Baranger K, Rivera S, Liechti FD, Grandgirard D, Bigas J, Seco J, et al. Endogenous and synthetic MMP inhibitors in CNS physiopathology. Prog Brain Res. 2014;214:313\u201351.","journal-title":"Prog Brain Res"},{"key":"5226_CR13","doi-asserted-by":"crossref","unstructured":"Paul R, Lorenzl S, Koedel U, Sporer B, Vogel U, Frosch M, et al. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann Neurol. 1998;44:592\u2013600.","DOI":"10.1002\/ana.410440404"},{"key":"5226_CR14","doi-asserted-by":"crossref","unstructured":"Lindberg RLP, Sorsa T, Tervahartiala T, Hoffmann F, Mellanen L, Kappos L, et al. Gelatinase B [matrix metalloproteinase (MMP)-9] and collagenases (MMP-8\/\u221213) are upregulated in cerebrospinal fluid during aseptic and bacterial meningitis in children. Neuropathol Appl Neurobiol. 2006;32:304\u201317.","DOI":"10.1111\/j.1365-2990.2006.00729.x"},{"key":"5226_CR15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1086\/313922","volume":"31","author":"D Leppert","year":"2000","unstructured":"Leppert D, Leib SL, Grygar C, Miller KM, Schaad UB, Hollander GA. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage in neurological sequelae. Clin Infect Dis. 2000;31:80\u20134.","journal-title":"Clin Infect Dis"},{"key":"5226_CR16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/INF.0000000000000249","volume":"33","author":"I Roine","year":"2014","unstructured":"Roine I, Pelkonen T, Bernardino L, Lauhio A, Tervahartiala T, Lappalainen M, et al. Predictive value of cerebrospinal fluid matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 concentrations in childhood bacterial meningitis. Pediatr Infect Dis J. 2014;33:675\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"5226_CR17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3940(98)00776-9","volume":"256","author":"I Azeh","year":"1998","unstructured":"Azeh I, Mader M, Smirnov A, Beuche W, Nau R, Weber F. Experimental pneumococcal meningitis in rabbits: the increase of matrix metalloproteinase-9 in cerebrospinal fluid correlates with leucocyte invasion. Neurosci Lett. 1998;256:127\u201330.","journal-title":"Neurosci Lett"},{"key":"5226_CR18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1128\/IAI.68.2.615-620.2000","volume":"68","author":"SL Leib","year":"2000","unstructured":"Leib SL, Leppert D, Clements J, Tauber MG. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun. 2000;68:615\u201320.","journal-title":"Infect Immun"},{"key":"5226_CR19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.nbd.2005.09.007","volume":"21","author":"J Sellner","year":"2006","unstructured":"Sellner J, Leib SL. In bacterial meningitis cortical brain damage is associated with changes in parenchymal MMP-9\/TIMP-1 ratio and increased collagen type IV degradation. Neurobiol Dis. 2006;21:647\u201356.","journal-title":"Neurobiol Dis"},{"key":"5226_CR20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/138955712798868977","volume":"12","author":"F Bahrami","year":"2012","unstructured":"Bahrami F, Morris DL, Pourgholami MH. Tetracyclines: drugs with huge therapeutic potential. Mini-Rev Med Chem. 2012;12:44\u201352.","journal-title":"Mini-Rev Med Chem"},{"key":"5226_CR21","doi-asserted-by":"crossref","unstructured":"Acharya MR, Venitz J, Figg WD, Sparreboom A. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist Updat. 2004;7:195\u2013208.","DOI":"10.1016\/j.drup.2004.04.002"},{"key":"5226_CR22","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1128\/IAI.01949-05","volume":"74","author":"DN Meli","year":"2006","unstructured":"Meli DN, Coimbra RS, Erhart DG, Loquet G, Bellac C, Tauber MG, et al. Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis. Infect Immun. 2006;74:3890\u20136.","journal-title":"Infect Immun"},{"key":"5226_CR23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/QCO.0000000000000416","volume":"31","author":"JP Bewersdorf","year":"2018","unstructured":"Bewersdorf JP, Grandgirard D, Koedel U, Leib SL. Novel and preclinical treatment strategies in pneumococcal meningitis. Curr Opin Infect Dis. 2018;31:85\u201392.","journal-title":"Curr Opin Infect Dis"},{"key":"5226_CR24","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1128\/IAI.01424-08","volume":"77","author":"R Colicchio","year":"2009","unstructured":"Colicchio R, Ricci S, Lamberti F, Pagliarulo C, Pagliuca C, Braione V, et al. The meningococcal ABC-type L-glutamate transporter GltT is necessary for the development of experimental meningitis in mice. Infect Immun. 2009;77:3578\u201387.","journal-title":"Infect Immun"},{"key":"5226_CR25","doi-asserted-by":"crossref","first-page":"e00688","DOI":"10.1128\/IAI.00688-18","volume":"87","author":"R Colicchio","year":"2019","unstructured":"Colicchio R, Pagliuca C, Ricci S, Scaglione E, Grandgirard D, Masouris I, et al. Virulence traits of a serogroup C meningococcus and isogenic cssA mutant, defective in surface-exposed sialic acid, in a murine model of meningitis. Infect Immun. 2019;87:e00688\u201318.","journal-title":"Infect Immun"},{"key":"5226_CR26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/CMR.13.1.144","volume":"13","author":"M van Deuren","year":"2000","unstructured":"van Deuren M, Brandtzaeg P, van der Meer JWM. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev. 2000;13:144\u201366.","journal-title":"Clin Microbiol Rev"},{"key":"5226_CR27","doi-asserted-by":"crossref","unstructured":"Pron B, Taha M-K, Rambaud C, Fournet J-C, Pattey N, Monnet J-P, et al. Interaction of Neisseria meningitidis with the components of the blood-brain barrier correlates with an increased expression of PilC. J Infect Dis. 1997;176:1285\u201392.","DOI":"10.1086\/514124"},{"key":"5226_CR28","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1309\/3489075U03LMK9AE","volume":"122","author":"J Guarner","year":"2004","unstructured":"Guarner J, Greer PW, Whitney A, Shieh W-J, Fischer M, White EH, et al. Pathogenesis and diagnosis of human meningococcal disease using immunohistochemical and PCR assays. Am J Clin Pathol. 2004;122:754\u201364.","journal-title":"Am J Clin Pathol"},{"key":"5226_CR29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s12028-011-9634-4","volume":"16","author":"ES Schut","year":"2012","unstructured":"Schut ES, Lucas MJ, Brouwer MC, Vergouwen MDI, van der Ende A, van de Beek D. Cerebral infarction in adults with bacterial meningitis. Neurocrit Care. 2012;16:421\u20137.","journal-title":"Neurocrit Care"},{"key":"5226_CR30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12880-015-0090-z","volume":"15","author":"K Miyazaki","year":"2015","unstructured":"Miyazaki K, Fukushima H, Kogeichi Y, Watanabe T, Norimoto K, Taoka T, et al. A case of meningococcal meningitis with multiple cerebellar microbleeds detected by susceptibility-weighted imaging. BMC Med Imaging. 2015;15:45.","journal-title":"BMC Med Imaging"},{"key":"5226_CR31","doi-asserted-by":"crossref","unstructured":"Ventura F, Bonsignore A, Portunato F, Orcioni GF, Varnier OE, De Stefano F. A fatal case of streptococcal and meningococcal meningitis in a 2-years-old child occurring as Waterhouse-Friderichsen syndrome. J Forensic Legal Med. 2013;20:678\u201382.","DOI":"10.1016\/j.jflm.2013.04.004"},{"key":"5226_CR32","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1186\/s12879-014-0726-6","volume":"14","author":"S Ricci","year":"2014","unstructured":"Ricci S, Grandgirard D, Wenzel M, Braccini T, Salvatore P, Oggioni MR, et al. Inhibition of matrix metalloproteinases attenuates brain damage in experimental meningococcal meningitis. BMC Infect Dis. 2014;14:726.","journal-title":"BMC Infect Dis"},{"key":"5226_CR33","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1128\/IAI.00073-14","volume":"82","author":"FD Liechti","year":"2014","unstructured":"Liechti FD, Grandgirard D, Leppert D, Leib SL. Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014;82:1710\u20138.","journal-title":"Infect Immun"},{"key":"5226_CR34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"5226_CR35","doi-asserted-by":"crossref","first-page":"e1000461","DOI":"10.1371\/journal.ppat.1000461","volume":"5","author":"U Koedel","year":"2009","unstructured":"Koedel U, Frankenberg T, Kirschnek S, Obermaier B, Hacker H, Paul R, et al. Apoptosis is essential for neutrophil functional shutdown and determines tissue damage in experimental pneumococcal menigitis. PLoS Pathog. 2009;5:e1000461.","journal-title":"PLoS Pathog"},{"key":"5226_CR36","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s11908-010-0116-1","volume":"12","author":"U Koedel","year":"2010","unstructured":"Koedel U, Klein M, Pfister H-W. Modulation of brain injury as a target of adjunctive therapy in bacterial meningitis. Curr Infect Dis Rep. 2010;12:266\u201373.","journal-title":"Curr Infect Dis Rep"},{"key":"5226_CR37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/CMR.16.3.415-429.2003","volume":"16","author":"M van der Flier","year":"2003","unstructured":"van der Flier M, Geelen SP, Kimpen JL, Hoepelman IM, Tuomanen EI. Reprogramming the host response in bacterial meningitis: how best to improve outcome? Clin Microbiol Rev. 2003;16:415\u201329.","journal-title":"Clin Microbiol Rev"},{"key":"5226_CR38","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jneuroim.2014.11.015","volume":"278","author":"T Barichello","year":"2015","unstructured":"Barichello T, Collodel A, Generoso JS, Sim\u00f5es LR, Moreira AP, Ceretta RA, et al. Targets for adjunctive therapy in pneumococcal meningitis. J Neuroimmunol. 2015;278:262\u201370.","journal-title":"J Neuroimmunol"},{"key":"5226_CR39","doi-asserted-by":"crossref","first-page":"108.e9","DOI":"10.1016\/j.cmi.2018.03.039","volume":"25","author":"M Klein","year":"2019","unstructured":"Klein M, Hohne C, Angele B, Hogen T, Pfister HW, Tufekci H, et al. Adjuvant non-bacteriolytic and anti-inflammatory combination therapy in pneumococcal meningitis: an investigation in a mouse model. Clin Microbiol Infect. 2019;25:108.e9\u2013108.e15.","journal-title":"Clin Microbiol Infect"},{"key":"5226_CR40","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.cmi.2016.01.007","volume":"22","author":"D van de Beek","year":"2016","unstructured":"van de Beek D, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek AT, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22:S37\u201362.","journal-title":"Clin Microbiol Infect"},{"key":"5226_CR41","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/brain\/124.9.1734","volume":"124","author":"SL Leib","year":"2001","unstructured":"Leib SL, Clements JM, Lindberg RLP, Heimgartner C, Loeffler JM, Pfister L-A, et al. Inhibition of matrix metalloproteinases and tumour necrosis factor \u03b1 converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain. 2001;124:1734\u201342.","journal-title":"Brain"},{"key":"5226_CR42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jneuroim.2004.01.026","volume":"151","author":"DN Meli","year":"2004","unstructured":"Meli DN, Loeffler JM, Baumann P, Neumann U, Buhl T, Leppert D, et al. In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-\u03b1 converting enzyme attenuates seizures and injury of the cerebral cortex. J Neuroimmunol. 2004;151:6\u201311.","journal-title":"J Neuroimmunol"},{"key":"5226_CR43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12974-015-0257-0","volume":"12","author":"FD Liechti","year":"2015","unstructured":"Liechti FD, Bachtold F, Grandgirard D, Leppert D, Leib SL. The matrix metalloproteinase inhibitor RS-130830 attenuates brain injury in experimental pneumococcal meningitis. J Neuroinflammation. 2015;12:43.","journal-title":"J Neuroinflammation"},{"key":"5226_CR44","doi-asserted-by":"crossref","first-page":"489","DOI":"10.55782\/ane-2014-2011","volume":"74","author":"X Liu","year":"2014","unstructured":"Liu X, Han Q. Efficacy of GM6001 as an adjuvant to ceftriaxone in a neonatal rat model of Streptococcus pneumoniae meningitis. Acta Neurobiol Exp (Wars). 2014;74:489\u201396.","journal-title":"Acta Neurobiol Exp (Wars)"},{"key":"5226_CR45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12974-018-1272-8","volume":"15","author":"L Muri","year":"2018","unstructured":"Muri L, Grandgirard D, Buri M, Perny M, Leib SL. Combined effect of non-bacteriolytic antibiotic and inhibition of matrix metalloproteinases prevents brain injury and preserves learning, memory and hearing function in experimental paediatric pneumococcal meningitis. J Neuroinflammation. 2018;15:233.","journal-title":"J Neuroinflammation"},{"key":"5226_CR46","doi-asserted-by":"crossref","first-page":"e00220","DOI":"10.1128\/AAC.00220-19","volume":"63","author":"L Muri","year":"2019","unstructured":"Muri L, Perny M, Zemp J, Grandgirard D, Leib SL. Combining ceftriaxone with doxycycline and daptomycin reduces mortality, neuroinflammation, brain damage, and hearing loss in infant rat pneumococcal meningitis. Antimicrob Agents Chemother. 2019;63:e00220\u201319.","journal-title":"Antimicrob Agents Chemother"},{"key":"5226_CR47","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1535370213508354","volume":"239","author":"T Barichello","year":"2014","unstructured":"Barichello T, Generoso JS, Michelon CM, Simoes LR, Elias SG, Vuolo F, et al. Inhibition of matrix metalloproteinases-2 and -9 prevents cognitive impairment induced by pneumococcal meningitis in Wistar rats. Exp Biol Med. 2014;239:225\u201331.","journal-title":"Exp Biol Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05226-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05226-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05226-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T23:52:33Z","timestamp":1723247553000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05226-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5226"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05226-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"15 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal experiments were authorised by the local ethics committee OPBA (\u2018Organismo Preposto al Benessere degli Animali\u2019; document no. 26094-X\/10) and the Italian Ministry of Health (document no. 815\/2015-PR and following amendments).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"505"}}